BA
TEVA icon

Ballast Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Ballast Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15
Closed -$452 – 364
2026
Q1 		$452 Buy
+15
New +$483 ﹤0.01% 391

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Ballast Advisors's TEVA Position: Q2 2026 in Review

Ballast Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 15 shares — an estimated $452 sold.

Ballast Advisors first reported a position in TEVA in Q1 2026 and held it in 1 quarter. The position peaked at $452 in Q1 2026. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Ballast Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ballast Advisors sold 15 Teva Pharmaceuticals shares in Q2 2026, an estimated $452.
  • Ballast Advisors first reported a position in Teva Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Ballast Advisors's Teva Pharmaceuticals position peaked at $452 in Q1 2026.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ballast Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.